Table 3.

Antimicrobial susceptibilities of the 61 CPE isolates (2011–2016, Reunion Island, France). ^a Two isolates harboured two carbapenemase-encoding genes: one K. pneumoniae isolate harboured bla_NDM-1 and bla_OXA-181, and one E. coli isolate harboured bla_NDM-1 and bla_VIM-2. ^b The clinical breakpoints for imipenem (0.125–4) were used to determine the susceptibility of the isolate of P. mirabilis. ^c Because of the intrinsic resistance of the P. mirabilis species to tigecycline, one isolate of P. mirabilis harbouring bla_NDM-1 was excluded for the calculation of non-susceptibility rate of tigecycline. The PK/PD clinical breakpoints for tigecycline (EUCAST 2019; 0.5–0.5) were used to determine the susceptibility of other isolates than E. coli. ^d Because of the intrinsic resistance of the S. marcescens and P. mirabilis species to colistin, one isolate of P.mirabilis harbouring bla_NDM-1 and 3 isolates of S.marcescens harbored bla_IMP-10 were excluded for the calculation of non-susceptibility rate of colistin (N.D.: not determined)

Antimicrobials	Carbapenemase-encoding genes (% of non-susceptible isolates)					MIC Range (mg/L)		MIC50 (mg/L)	MIC90 (mg/L)
	blaNDMa	blaIMI	blaIMP-10	blaOXA-181	Total	Min.	Max.
	(n = 50)	(n = 7)	(n = 3)	(n = 1)	(n = 61)
Ertapenem	96	71.4	100	0	91.8	0.25	32	8	32
Imipenem	66b	100	100	0	70.5b	0.5	32	6	32
Meropenem	84	14.3	100	0	75.4	1	32	6	32
Tigecycline	34.7c	14.3	100	0	33.3c	0.032	24	0.38	6
Colistin	6.1d	100	NDd	0	17.5d	0.06	64	0.25	32
Fosfomycin	22	0	100	0	23	0.125	1024	12	128